Chengzhi Ding

618 citations
25 papers · 503 indexed · h-index 11
Topics
MicroRNA in disease regulation (8 papers)Esophageal Cancer Research and Treatment (5 papers)Circular RNAs in diseases (5 papers)
Partner nations
ChinaHong Kong

In The Last Decade

Chengzhi Ding

24 papers receiving 498 citations

Peers

Chengzhi Ding
Comparison fields: 5 of 80
  • Molecular Biology 297
  • Cancer Research 271
  • Immunology 125
  • Pulmonary and Respiratory Medicine 63
  • Epidemiology 51
Replace Ainhoa Alberro with:
Ainhoa Alberro Spain
Xuefeng Zang China
Matías Sáenz-Cuesta Spain
Tingting Mills United States
Manli Yu China
Arulmozhi D. Kandasamy Canada
Sarah Franco United States
Yunye Ning China
Chengzhi Ding relative to Ainhoa Alberro Spain Ainhoa Alberro's profile →
Citations per field
00.5×10×
Ainhoa Alberro · 1×
Citations per year

Countries citing papers authored by Chengzhi Ding

Since Specialization
Citations

This map shows the geographic impact of Chengzhi Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengzhi Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengzhi Ding more than expected).

Fields of papers citing papers by Chengzhi Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengzhi Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengzhi Ding. The network helps show where Chengzhi Ding may publish in the future.

Co-authorship network of co-authors of Chengzhi Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Chengzhi Ding. A scholar is included among the top collaborators of Chengzhi Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengzhi Ding. Chengzhi Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 0
3 1
4 2
5 3
6 13
7 37
8 6
9 19
10 32
11 1
12 59
13 5
14 10
15 15
16 52
17 1
18 69
19 123
20
[Effect of Shenfu injection on expression of lipopolysaccharide --induced microRNA-146a in alveolar macrophages].
2

About Chengzhi Ding

Chengzhi Ding is a scholar working on Cancer Research, Immunology and Internal Medicine, having authored 25 papers that have together received 503 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (8 papers), Esophageal Cancer Research and Treatment (5 papers) and Circular RNAs in diseases (5 papers). The work is most often cited by research in Cancer Research (271 citations), Immunology (125 citations) and Molecular Biology (297 citations). Chengzhi Ding has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Qiang Shao, Fen Liu, Zhenguo Zeng, Cheng Nie, Yong Li, Kejian Qian, Kejian Qian, Qing Cheng, Honghan Gong and Weifeng Zhu. Their work appears in journals such as Frontiers in Immunology, European Journal of Pharmacology and Journal of Cellular Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026